Daniel Geh

Newcastle Upon Tyne, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications

Improving surgical treatments for hepatocellular carcinoma.

Improving surgical treatments for hepatocellular carcinoma.

Journal: Nature reviews. Gastroenterology & hepatology
Published: October 14, 2025

Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening.

Precision-cut tumor slices for modeling hepatocellular carcinoma enable at-scale drug screening.

Journal: Hepatology communications
Published: October 03, 2024

Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study.

Impact of COVID-19 on 1-Year Survival Outcomes in Hepatocellular Carcinoma: A Multicenter Cohort Study.

Journal: Cancers
Published: May 22, 2023

ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.

ST3 beta-galactoside alpha-2,3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer.

Journal: Communications biology
Published: April 11, 2023

Harnessing neutrophil plasticity for HCC immunotherapy.

Harnessing neutrophil plasticity for HCC immunotherapy.

Journal: Essays in biochemistry
Published: February 16, 2023

c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.

c-Rel-dependent Chk2 signaling regulates the DNA damage response limiting hepatocarcinogenesis.

Journal: Hepatology (Baltimore, Md.)
Published: May 23, 2022

Neutrophils as potential therapeutic targets in hepatocellular carcinoma.

Neutrophils as potential therapeutic targets in hepatocellular carcinoma.

Journal: Nature reviews. Gastroenterology & hepatology
Published: December 06, 2021

CXCR2 inhibition enables NASH-HCC immunotherapy.

CXCR2 inhibition enables NASH-HCC immunotherapy.

Journal: Gut
Published: October 05, 2021

COVID-19 and liver cancer: lost patients and larger tumours.

COVID-19 and liver cancer: lost patients and larger tumours.

Journal: BMJ open gastroenterology
Published: September 28, 2021

Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions.

Metabolic dysfunction and cancer in HCV: Shared pathways and mutual interactions.

Journal: Journal of hepatology
Published: August 31, 2021

Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?

Sulfatase-2 from Cancer Associated Fibroblasts: An Environmental Target for Hepatocellular Carcinoma?

Journal: Liver cancer
Published: August 11, 2021

NAFLD-Associated HCC: Progress and Opportunities.

NAFLD-Associated HCC: Progress and Opportunities.

Journal: Journal of hepatocellular carcinoma
Published: January 18, 2021
Showing 1-12 of 16

Last Updated: 09/26/2026